S-1/A: BNB Plus Corp. Registers 18.7M Shares for Resale, Advances BNB Strategy

BNB Plus Corp. files an S-1/A to register 18.7 million shares for resale by selling stockholders, detailing its new BNB-focused digital asset treasury strategy and ongoing LineaRx biopharmaceutical business.

Summary

• The filing registers up to 18,728,341 shares of common stock for resale by various selling stockholders.
• These shares originate from a Cash Private Placement and a Crypto Private Placement, involving common shares, pre-funded warrants, Series E warrants, Placement Agent Warrants, Advisory Warrants, and Consultant Warrants.
• The company, formerly Applied DNA Sciences, Inc., has rebranded to BNB Plus Corp. and changed its Nasdaq ticker symbol to BNBX.
• The primary strategy is now a Digital Asset Treasury (DAT) focused on accumulating BNB, the native cryptocurrency of the Binance blockchain ecosystem, to produce yield via Binance native and other decentralized finance (DeFi) opportunities.
• The company's secondary business, through its LineaRx, Inc. subsidiary, continues to commercialize proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets.
• The Private Placement generated $26.7 million in gross proceeds, with a potential for up to an additional $30.8 million from future warrant exercises, totaling up to $57.6 million.
• As of December 15, 2025, the company holds approximately 18,830 BNB tokens through direct holdings and OBNB Trust Units, including a recent opportunistic deployment of approximately $3 million to acquire BNB at an average price of $895 per token.
• Build & Build, LLC (Delaware) and BNBX Ltd. (British Virgin Islands) were formed to house certain cryptocurrency assets.
• Cypress LLC was engaged as the Services Provider for discretionary asset management of the BNB Strategy, with a 5-year initial term, compensated with a 1.25% annual management fee and a 10% incentive fee on net returns.
• Cypress Management LLC was engaged as a Strategic Advisor, receiving a monthly fee of $60,000 and 1,986,634 Advisory Warrants.
• Ground Tunnel Capital LLC was engaged for advisory and marketing services, with compensation including an upfront fee of $1,000,000, quarterly payments of $250,000 from December 2025 until September 2027, and Consultant Warrants for 1% of the fully diluted outstanding equity.
• Stockholders approved the issuance of shares for Crypto Pre-Funded Warrants and Series E-2 Warrants, an increase in authorized common stock from 200,000,000 to 500,000,000 shares, and an increase of 5,000,000 shares reserved for issuance under the 2020 Equity Incentive Plan.
• An At The Market (ATM) Offering Agreement was established with Lucid Capital Markets, LLC to sell up to $8,157,932 of common stock; as of December 15, 2025, 10,759 shares were sold for $31,791 in net proceeds.
• Patrick Horsman was appointed Chief Investment Officer on October 1, 2025, receiving $29,167 monthly consulting compensation.

Sentiment

Score: 5

Explanation: The company is making a bold strategic pivot into the high-risk, high-reward digital asset treasury space, backed by recent capital raises and strategic partnerships. This move, coupled with the ongoing LineaRx biopharmaceutical business, offers potential for significant upside. However, the inherent volatility and regulatory uncertainties of the cryptocurrency market, the unproven nature of the BNB yield strategy, potential for substantial shareholder dilution from warrant exercises and future offerings, and the 'going concern' qualification in a prior auditor's report introduce considerable downside risk and uncertainty. The dual business model also adds complexity.

Positives

• Successfully completed private placements, raising $26.7 million in gross proceeds, with potential for an additional $30.8 million from warrant exercises, totaling up to $57.6 million.
• Executed a strategic pivot to a digital asset treasury (DAT) model focused on BNB, aiming to generate yield from Binance ecosystem and DeFi opportunities, indicating a forward-looking approach to capital management.
• Accumulated approximately 18,830 BNB tokens as of December 15, 2025, including a recent $3 million opportunistic deployment, demonstrating active implementation of the new strategy.
• Established strategic partnerships with Cypress LLC for digital asset management and Cypress Management LLC for strategic advisory services, bringing specialized expertise to the new BNB strategy.
• Stockholder approval for key corporate actions, including increasing authorized shares and expanding the equity incentive plan, provides flexibility for future growth and talent retention.
• Continued development and commercialization of LineaRx's nucleic acid production solutions offer diversification and potential for growth in the biopharmaceutical and diagnostics markets.

Negatives

• The auditor's report from Marcum LLP for the fiscal year ended September 30, 2024, included an explanatory paragraph regarding the company's ability to continue as a going concern.
• A significant portion of the filing relates to the resale of shares by selling stockholders, which does not directly generate proceeds for the company, except from warrant exercises.
• The Chairman of the Board, Joshua Kruger, and Chief Investment Officer, Patrick Horsman, are members or affiliates of the Services Provider and Strategic Advisor, which together receive approximately $720,000 annually, raising potential conflict of interest concerns.
• The company is a 'smaller reporting company' and has elected to comply with certain reduced reporting requirements, which may result in less comprehensive disclosure compared to larger public companies.
• The 'only for-cause' director removal provision in the Certificate of Incorporation and By-Laws has been deemed invalid by Delaware court precedent, indicating a potential weakness in corporate governance.

Risks

• Investing in the company's securities involves a high degree of risk, and investors may lose all or part of their investment.
• There is no assurance that the company will be successful in its BNB Strategy, which is an unproven yield generation strategy.
• The price of BNB and other cryptocurrencies is highly volatile, which could materially and adversely affect the value of the company's digital asset holdings and its common stock.
• The company faces risks related to its ability to raise and deploy capital effectively for its BNB Strategy.
• The price of the company's common stock may be highly correlated to the price of the digital assets it holds.
• Increased competition in both the digital asset and biopharmaceutical industries could adversely affect the company's business operations.
• Uncertainties exist regarding the treatment of crypto assets for U.S. and foreign tax purposes, which could impact the company's financial results.
• The BNB ecosystem faces regulatory uncertainties, technological competition, and market volatility common to the cryptocurrency space.
• U.S. regulators have scrutinized burn mechanisms in past enforcement actions, and if BNB's burn mechanism were similarly classified, it could increase the likelihood of BNB being deemed a security, leading to heightened regulatory restrictions, adversely affecting its liquidity and price.
• A significant majority of daily BNB trading volume occurs on the Binance Exchange, controlled by Binance, and most BNB in circulation is reportedly held by Binance's founder, raising concerns about potential price and trading volume manipulation.
• Allegations of BNB price or volume manipulation could result in regulatory actions against Binance and/or loss of confidence in BNB, negatively impacting the company's common stock price.
• The company's dependence on Binance and its affiliates for the health and credibility of the BNB ecosystem subjects it to material counterparty, reputational, and regulatory risks outside of its control.
• The OBNB Trust Units held by the company are potentially illiquid, and the company may have limited ability to sell, transfer, or redeem them for the underlying BNB assets.
• Risks related to market volatility, cybersecurity, and custody of digital assets are inherent in the BNB Strategy.
• Potential changes in laws or accounting standards relating to cryptocurrency and regulatory developments affecting BNB could adversely impact the company.
• The company may need additional financing, which could require the issuance of additional shares of common stock, preferred stock, or other debt or equity securities, leading to dilution of existing stockholders.
• The demand for products and services provided by the LineaRx subsidiary is a risk factor for that segment of the business.
• The company's ability to sell or otherwise monetize its LineaRx subsidiary is uncertain.
• The volatility of, and decline in, the company's stock price is a general market risk.

Future Outlook

The company intends to use net proceeds from warrant exercises primarily for the continued development and implementation of its BNB Strategy, as well as for working capital and general corporate purposes. It believes the BNB Strategy can produce potential yield through participation in the Binance Launch Pool, native staking on Binance Smart Chain, liquidity providing, and BNB collateralization. The company plans to pursue opportunities to sell OBNB Trust Units for cash to purchase additional BNB or access underlying BNB assets. The LineaRx subsidiary is projected to significantly narrow its losses for FY26Q1 (ending December 31, 2025) and approach profitability, with a business strategy to advance nucleic acid production solutions for potential future sales and/or licensing agreements. The BNB burn policy is intended to have a deflationary effect, potentially increasing the value and price of BNB.

Management Comments

• We are a digital asset treasury (DAT) company that has adopted BNB, the native cryptocurrency of the Binance blockchain ecosystem as our primary reserve asset.
• Our current strategy is to primarily focus our resources on our BNB-focused DAT strategy wherein we manage digital assets, primarily in the native cryptocurrency of the Binance Coin blockchain commonly referred to as BNB, including staking, restaking, and liquid staking of BNB, and participation in other unique Binance ecosystem and DeFi yield opportunities.
• Currently, the Company is in the process of accumulating BNB tokens and building the framework necessary to implement its BNB Strategy.
• Once launched, we believe our BNB Strategy can produce potential yield via the implementation of one or more of the below strategies.
• The Company has discretion on whether and when to file the Charter Amendment and, as of the date of this report, has made no decision.
• Ms. Murrah's resignation as Chairperson is not the result of any dispute or disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices.

Industry Context

The company is undergoing a significant strategic pivot into the digital asset treasury space, specifically focusing on BNB within the Binance ecosystem, which is the world's largest cryptocurrency exchange. This aligns with a broader trend of corporate treasuries exploring digital assets for yield generation, albeit in a high-risk, high-reward environment characterized by rapid innovation and regulatory uncertainty. Concurrently, the LineaRx subsidiary operates in the biopharmaceutical and diagnostics markets, specializing in nucleic acid production, a critical and growing area for advanced biotherapeutics like gene therapies and mRNA vaccines. This dual business model positions the company across two distinct, high-growth, but also high-risk, industries.

Comparison to Industry Standards

• The BNB Chain, central to the company's digital asset strategy, boasts publicly reported maximum theoretical transactions per second exceeding 2,000 and low gas fees of approximately $0.01 per transaction, positioning it competitively within the broader blockchain ecosystem.
• LineaRx's LineaDNA platform is presented as an alternative to traditional plasmid-based DNA manufacturing, offering advantages such as cell-free production, rapid synthesis, and minimal purification steps, which are key differentiators in the biopharmaceutical manufacturing sector.
• LineaRNAP and LineaIVT technologies are claimed to result in higher mRNA yields, increased mRNA integrity, and reduced double-stranded RNA (dsRNA) contamination compared to conventional methods, addressing critical quality and efficiency benchmarks in mRNA therapeutics production.

Management Changes

Corporate Governance

Related Party Transactions

• Joshua Kruger, Chairman of the Board and a Director, is a member of Cypress LLC (Services Provider) and Cypress Management LLC (Strategic Advisor), which together provide services to the company for compensation of approximately $720,000 annually.
• Patrick Horsman, Chief Investment Officer, is an affiliate of Cypress LLC and Cypress Management LLC, and receives monthly consulting compensation of $29,167.
• James Haft, a Selling Stockholder, is an adviser to Cypress Management LLC.
• Cypress LLC and Cypress Management LLC are listed as Selling Stockholders.
• Lucid Capital Markets, LLC acted as the sole placement agent for the Private Placement and the sales agent for the At The Market Offering Agreement, and is a Selling Stockholder. John Lipman, a Selling Stockholder, is an employee of Lucid Capital Markets, LLC.
• Ground Tunnel Capital LLC, a Selling Stockholder, provides advisory and marketing services to the company under consulting arrangements.

Stakeholder Impact

• Shareholders face potential dilution from the exercise of warrants and future capital raises, including the At The Market offering and the increased authorized share count. The value of their investment is now highly exposed to the volatile cryptocurrency market.
• Employees may benefit from the increased shares reserved for the equity incentive plan, potentially enhancing compensation and retention.
• Management, including the CEO, CFO, and CIO, have employment/consulting agreements and equity incentives, aligning their interests with the company's performance.
• Creditors may view the capital raised and potential future proceeds as a positive for the company's financial stability, potentially reducing credit risk, though the high-risk nature of the new strategy introduces new uncertainties.

Next Steps

• Selling stockholders may sell the registered securities from time to time on The Nasdaq Capital Market or in private transactions.
• The company will receive proceeds from the cash exercise of warrants, which will be used primarily for the continued development and implementation of its BNB Strategy, as well as for working capital and general corporate purposes.
• The company plans to pursue opportunities to sell OBNB Trust Units for cash to purchase additional BNB or access the underlying BNB assets.
• The company is in the process of accumulating BNB tokens and building the framework necessary to implement its BNB Strategy.
• The LineaRx subsidiary is projected to significantly narrow its losses for FY26Q1 (ending December 31, 2025) and approach profitability.
• The company has discretion on whether and when to file the Charter Amendment to increase authorized shares.
• The company may continue to offer and sell shares through the At The Market Offering Agreement.

Key Dates

Recommendation

The company is in a transitional phase with a high-risk, high-reward strategy in the volatile cryptocurrency market, alongside its existing biopharmaceutical business. While recent capital raises and strategic initiatives are positive, the significant uncertainties surrounding the BNB strategy's success, potential for dilution, and the 'going concern' issue from a prior audit report suggest a cautious stance. Existing investors should hold to observe the execution of the new strategy and market developments, while new investors might find the risk profile too high without clearer operational results.

Keywords

BNB Plus Corp, BNBX, digital asset treasury, cryptocurrency, BNB strategy, Binance, DeFi, LineaRx, nucleic acid production, biopharmaceuticals, warrants, private placement, stock resale, Nasdaq, corporate governance, risk factors, capital raise, stockholder approval, ATM offering, Chief Investment Officer, Cypress LLC, Ground Tunnel Capital LLC, Osprey BNB Chain Trust, OBNB, S-1/A